Revolution Medicines advisor sells 27,160 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Stephen Michael Kelsey, a Senior Advisor to the Chief Executive Officer, exercised options for 27,160 Revolution Medicines, Inc. shares on November 16, 2026, at an exercise price of $18.56 per share. He sold 27,160 shares that day in six transactions, at reported weighted-average prices of $166.7506, $167.6619, $168.6375, $169.4561, $170.3957 and $171.6500 per share.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F8 | 27,160 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 27,160 | $18.56 | $504K |
| Sale | Common Stock F1, F2 | 11,542 | $166.7506 | $1.92M |
| Sale | Common Stock F1, F3 | 3,627 | $167.6619 | $608K |
| Sale | Common Stock F1, F4 | 8,039 | $168.6375 | $1.36M |
| Sale | Common Stock F1, F5 | 3,052 | $169.4561 | $517K |
| Sale | Common Stock F1, F6 | 700 | $170.3957 | $119K |
| Sale | Common Stock F1, F7 | 200 | $171.65 | $34K |
Footnotes (8)
- F1. Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on August 17, 2026.
- F2. The transaction was executed in multiple trades at prices ranging from $166.14 to $167.13, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3. The transaction was executed in multiple trades at prices ranging from $167.14 to $168.13, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4. The transaction was executed in multiple trades at prices ranging from $168.15 to $169.13, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F5. The transaction was executed in multiple trades at prices ranging from $169.15 to $170.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F6. The transaction was executed in multiple trades at prices ranging from $170.22 to $170.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F7. Includes 65,613 restricted stock units.
- F8. Fully vested.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average sale price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Were Stephen Michael Kelsey's RVMD transactions made under a 10b5-1 plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.